| Literature DB >> 33367149 |
Pınar Alkım Ulutaş1, Funda Kıral1, Bülent Ulutaş2, Gamze Sevri Ekren Aşıcı1.
Abstract
INTRODUCTION: Clinoptilolite has antiviral, antibacterial, anti-inflammatory, antidiabetic, and anticancer properties due to its biological activities. In various cancer cell culture studies, it has been reported effective against tumour cells and gave positive results in treatment of various tumours in dogs. No study was found on the effects of the nanoparticulate form, nanoclinoptilolite, on cancer cells. The aim of this study was to determine its cytotoxic and apoptotic effects in canine osteosarcoma (OSA) cell culture.Entities:
Keywords: BAX and BCL2 expression; apoptosis; canine osteosarcoma cell line; caspase-3 and -7; nanoclinoptilolite
Year: 2020 PMID: 33367149 PMCID: PMC7734687 DOI: 10.2478/jvetres-2020-0063
Source DB: PubMed Journal: J Vet Res ISSN: 2450-7393 Impact factor: 1.744
Fig. 1Effect of nanoclinoptilolite on cell viability of canine OSA D-17
Effect of nanoclinoptilolite on cell viability of canine D-17 OSA. The results represent the mean ± standard deviation
| Nanoclinoptilolite concentration (μg/mL) | 24 h | 48 h | 72 h | ||||||
|---|---|---|---|---|---|---|---|---|---|
| % Viability | X | P | % Viability | X | P | % Viability | X | P | |
| Control | 100 ± 5.66 | 100 ± 6.09 | 100 ± 3.15 | ||||||
| 10 | 92.62 ± 8.29 | >0.05 | 60.24 ± 5.50 | *** | 56.08 ± 3.57 | *** | |||
| 20 | 81.45 ± 5.11 | *** | 48.50 ± 1.83 | *** | 31.95 ± 2.24 | *** | |||
| 30 | 69.35 ± 2.24 | *** | 37.27 ± 2.25 | *** | 23.23 ± 6.89 | *** | |||
| 40 | 61.66 ± 3.01 | *** | 30.12 ± 2.23 | *** | 19.87 ± 5.45 | *** | |||
| 50 | 56.88 ± 2.45 | *** | 26.16 ± 4.14 | *** | 15.14 ± 7.29 | *** | |||
| 75 | 51.92 ± 2.02 | *** | 21.19 ± 0.42 | *** | 12.02 ± 1.70 | *** | |||
| 100 | 48.08 ± 1.87 | *** | 19.14 ± 1.55 | *** | 10.31 ± 0.26 | *** | |||
| 150 | 44.60 ± 1.80 | *** | 18.19 ± 0.53 | *** | 9.41 ± 0.15 | *** | |||
| 200 | 43.80 ± 3.91 | *** | 18.00 ± 0.74 | *** | 9.92 ± 0.28 | *** | |||
* P < 0.05; ** P < 0.01; *** P < 0.001 compared to control
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Live/apoptotic/necrotic cell ratios in canine D-17 OSA cells treated for 24 h with 10, 20, and 30 μg/mL of nanoclinoptilolite and in control group cells
| % live | % apoptotic | % dead | |
|---|---|---|---|
| Control | 92.3 ± 2.36 | 7.62 ± 1.83 | 0.12 ± 0.017 |
| 10 μg/mL | 93.65 ± 1.61 | 5.78 ± 0.87 | 0.57 ± 0.18 |
| 20 μg/mL | 91.57 ± 0.43 | 7.60 ± 0.32 | 0.95 ± 0.004 |
| 30 μg/mL | 86.65 ± 0.41 | 12.77 ± 0.51 | 0.52 ± 0.07 |
| P | 0.020 | 0.031 | 0.05 |
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Fig. 2Caspase-3 and -7 activity after treatment with different concentrations of nanoclinoptilolite in canine D-17 OSA cells. Treatment over 24 h: A – control; B – 10 μg/mL; C– 20 μg/mL; D – 30 μg/mL. Treatment over 48 h: E – control; F – 10 μg/mL; G – 20 μg/mL; H– 30 μg/mL
Live/apoptotic/necrotic cell ratios in canine D-17 OSA cells treated for 48 h with 10, 20, and 30 μg/mL of nanoclinoptilolite and in control group cells
| % live | % apoptotic | % dead | |
|---|---|---|---|
| Control | 92.63 ± 0.63 | 7.25 ± 0.73 | 0.22 ± 0.04 |
| 10 g/mL | 91.3 ± 0.41 | 8.53 ± 0.93 | 0.17 ± 0.02 |
| 20 μg/mL | 85.35 ± 0.30 | 14.2 ± 0.5 | 0.45 ± 0.09 |
| 30 μg/mL | 23.8 ± 1.96 | 23.8 ± 1.93 | 1.2 ± 0.03 |
| P | 0.020 | 0.031 | 0.05 |
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Statistical difference between groups with different letters in the same column is significant
Effect of nanoclinoptilolite on the Bax/Bcl-2 ratio in canine D-17 OSA cells for 24 and 48 h (* P<0.05)
| Nanoclinoptilolite concentration | 24 h | 48 h |
|---|---|---|
| 10 μg/mL | 0.44 | 3.00 |
| 20 μg/mL | 0.44 | 8.88 |
| 30 μg/mL | 0.75 | 14.24 |
Fig. 3Effect of nanoclinoptilolite on the BAX/BCL-2 ratio in canine D-17 OSA cells
Primer sequences used for qRT-PCR
| NCBI reference sequence | Gene | Forward primer (5´→3´) | Reverse primer (5´→3´) |
|---|---|---|---|
| AGTCAAGGCTGAGAACGGGAAA | TCCACAACATACTCAGCACCAGC | ||
| NM_001002949.1 | CATGCCAAGAGGGAAACACCAGAA | GTGCTTTGCATTCTTGGATGAGGG | |
| NM_001003011.1 | TTCCGAGTGGCAGCTGAGATGTTT | TGCTGGCAAAGTAGAAGAGGGCAA | |